bioMerieux (OTCMKTS:BMXMF) Shares Gap Down – Here’s What Happened

bioMerieux (OTCMKTS:BMXMF)’s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $105.41, but opened at $84.29. bioMerieux shares last traded at $84.29, with a volume of 200 shares.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on BMXMF. BNP Paribas Exane lowered bioMerieux to a “neutral” rating in a research note on Wednesday, January 28th. Deutsche Bank Aktiengesellschaft downgraded bioMerieux from a “buy” rating to a “hold” rating in a report on Friday, April 24th. Finally, Zacks Research raised shares of bioMerieux to a “hold” rating in a research report on Tuesday. Four analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Hold”.

bioMerieux Trading Down 5.2%

The firm has a fifty day moving average of $107.96 and a 200 day moving average of $118.41. The company has a current ratio of 2.39, a quick ratio of 1.48 and a debt-to-equity ratio of 0.08.

About bioMerieux

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.